Conferences IAS 2015
Other Infections
IAS 2015: Bone Loss Slows, but Continues Long-term in HIV-positive People on Antiretroviral Therapy
- Details
- Category: Bone Loss
- Published on Wednesday, 09 September 2015 00:00
- Written by Liz Highleyman
People with HIV experienced a decrease in bone density at the hip and spine during their first 2 years after starting antiretroviral therapy (ART). While bone loss slowed after 96 weeks, it continued to decline more rapidly among HIV-positive people compared with the usual age-related bone loss seen in HIV-negative people over 7 years, researchers reported at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
IAS 2015: The TPP and Access to HIV and HCV Treatment [VIDEO]
- Details
- Category: HIV Policy & Advocacy
- Published on Wednesday, 09 September 2015 00:00
- Written by Gregory Fowler
The Trans-Pacific Partnership trade agreement, now under consideration, will heavily impact the availability of medications for HIV and viral hepatitis, both in middle-income countries and in high-income countries such as Canada that rely on generic drugs, advocates said at a Médecins Sans Frontières media briefing at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
IAS 2015: Many People with Long-term HIV Infection Do Not Achieve Full CD4 Cell Recovery
- Details
- Category: HIV Disease Progression
- Published on Wednesday, 02 September 2015 00:00
- Written by Liz Highleyman
One-third of people who started combination antiretroviral therapy (ART) many years ago using first-generation protease inhibitors did not achieve complete immunological recovery with normal CD4 T-cell counts despite good viral suppression, according to a French study presented at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Vancouver.
Half of U.S. Gay Men Using Dating Apps Have Interacted with a PrEP User
- Details
- Category: Treatment as Prevention
- Published on Wednesday, 09 September 2015 00:00
- Written by Roger Pebody
Almost half of American gay men recruited to participate in a survey via advertising on a major mobile phone dating app say that at least one potential sexual partner has said that he was taking HIV pre-exposure prophylaxis (PrEP), and even more have interacted with someone who said that he was HIV-positive but had an undetectable viral load. Many of these potential partners were looking for sex without a condom, according to the survey results, published in the August 21 online edition ofJournal of Acquired Immune Deficiency Syndromes.
IAS 2015: Gay Men Are Using Nuanced Sero-adaptive Behaviors to Prevent HIV Infection
- Details
- Category: HIV Sexual Transmission
- Published on Wednesday, 02 September 2015 00:00
- Written by Roger Pebody
There is evidence that some groups of Australian and American gay men are considering HIV-positive partners’ undetectable viral load and the time elapsed since an HIV-negative partner last tested when making decisions about using condoms, according to studies presented at the recent 8th International AIDS Society Conference in Vancouver.
IAS 2015: Peer-Led Intervention Lowers HIV Infections Among Drug Injectors in Ukraine
- Details
- Category: Injection Drug Use
- Published on Tuesday, 08 September 2015 00:00
- Written by Roger Pebody
A cluster-randomized trial in Ukraine has shown that a peer education project reduced new HIV infections in people who inject drugs by 41%, researchers reported at the recent 8th Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
IAS 2015: PrEP Adherence, Sexual Behavior, and HIV and STI Incidence [VIDEO]
- Details
- Category: Pre-exposure Prophylaxis (PrEP)
- Published on Wednesday, 02 September 2015 00:00
- Written by Gregory Fowler
An open-label Truvada pre-exposure prophylaxis (PrEP) demonstration project, which included more than 500 mostly gay and bisexual men in San Francisco, Miami, and Washington, DC, showed that adherence was generally good overall -- especially among people at highest risk for HIV infection -- but there were some important disparities, researchers reported at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Vancouver.
IAS 2015: Rilpivirine + Darunavir HIV Maintenance Regimen Matches Standard 3-Drug ART
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 08 September 2015 00:00
- Written by Liz Highleyman
A NRTI-sparing dual antiretroviral regimen consisting of the NNRTI rilpivirine (Edurant) plus the boosted HIV protease inhibitor darunavir (Prezista) maintained viral suppression and was well-tolerated by people who switched from a standard 3-drug regimen, according to results from the PROBE study presented at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver.
IAS 2015: Peer or Community Interventions Improve Outcomes for Mothers with HIV
- Details
- Category: Pregnancy & HIV MTCT
- Published on Monday, 31 August 2015 00:00
- Written by Carole Leach-Lemens
Peer- and community-based interventions can significantly increase retention in care of mothers with HIV and improve attendance at early prenatal clinic visits, according to results from 2 large multi-country studies presented last month at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015) in Vancouver.
More Articles...
- IAS 2015: HIV+ People with Asymptomatic Cognitive Impairment More Likely to Develop Symptoms
- IAS 2015: Estrogen May Block HIV Reactivation, Hints at Gender Differences in Viral Reservoirs
- IAS 2015: ADAPT Study Shows PrEP Feasibility [VIDEO]
- IAS 2015: Fatty Liver May Contribute to Higher Risk of Death for HIV/HCV Coinfected People
- IAS 2015: Accessing Hepatitis C Treatment [VIDEO]
- IAS 2015: Information about HIV Treatment as Prevention Lessens Stigma and Increases Testing
- IAS 2015: HIV Treatment Scale-up Linked to Reduced Mortality Among Vancouver Drug Injectors
- IAS 2015: HIV+ Youth Are Less Likely than Adults to Achieve Viral Suppression on ART
- IAS 2015: Broadly Neutralizing Antibodies Against HIV [VIDEO]
- IAS 2015: First Brazilian Data Reinforce Evidence that PrEP is Mostly Used by Those at Greatest Risk
- IAS 2015: Innovative Linkage to Care Approaches Boost Clinic Visits, HIV Treatment Uptake in African Study
- IAS 2015: HIV Self-Testing May Help "Hard to Reach" Learn Their Status, but Uncertainties Remain
- IAS 2015: Ryan and Julie Lewis -- The 30/30 Project [VIDEO]
- IAS 2015: HIV and Hepatitis B Coinfected People Can Safely Switch to Simpler TAF Single-Tablet Regimen
- IAS 2015: PrEP and the Risk of Hepatitis C Virus Infection [VIDEO]
- Updated Guidelines for Pregnant Women with HIV and Preventing Mother-to-Child Transmission
- IAS 2015: High Adherence and No HIV Infections Seen in Heterosexual PrEP Study in Botswana
- IAS 2015: Implant and Injectable Hormonal Contraception Most Effective Methods for Women with HIV
- IAS 2015: A Community Perspective on HIV Prevention Science [VIDEO]
- IAS 2015: Altered Cholesterol Metabolism May Protect Immune Cells of Non-Progressors
- IAS 2015: Indiana HIV Outbreak -- Lessons about Containing Local Outbreaks and Harm Reduction
- IAS 2015: START Supports ART For All [VIDEO]
- IAS 2015: WAVES Shows Elvitegravir Regimen Beats Boosted Atazanavir for Women with HIV
- IAS 2015: Daclatasvir + Sofosbuvir Cures Most Coinfected People in French Compassionate Use Study
- IAS 2015: Pros and Cons of PrEP -- Volunteers Recount their Experiences in ADAPT Study
- IAS 2015: Intensification of ART Reduces Risk of Late-term Mother-to-Child HIV Transmission
- IAS 2015: Young Gay Men at Lower Risk for HIV than Previous Generations, but Racial Disparities Persist
- IAS 2015: Zinc Finger Nuclease Genome Editing [VIDEO]
- IAS 2015: People with Hepatitis B Can Safely Use Truvada PrEP for HIV Prevention
- IAS 2015: Cash to Stay in School Didn't Reduce HIV Incidence, but Attendance Protects Young Women
- IAS 2015: Cash Encourages Circumcision, Prevention of Mother-to-Child HIV Transmission
- IAS 2015: Targets Proliferate in HIV Cure Research
- IAS 2015: Interferon-free Hepatitis Treatment Highly Effective for HIV/HCV Coinfected People
- IAS 2015: Vancouver's HIV Treatment as Prevention Success Also Due to Harm Reduction
- IAS 2015: Gay Youth PrEP Study Finds Good Retention and Reasonable Adherence
- IAS 2015: Fibrosis Regression Linked to Reduced Complications and Death in HIV/HCV Coinfected
- IAS 2015: U.S. PrEP Demo Project Finds People at Highest HIV Risk Take PrEP Most Consistently
- IAS 2015: Treatment Cascades Show 90-90-90 Goals Reachable, Eastern Europe Lags Behind Africa
- IAS 2015: Test and Treat Studies and African Country Experience Show 90-90-90 Targets Are Achievable
- IAS 2015: Switching to Tenofovir Alafenamide Keeps HIV Suppressed, Helps Kidneys and Bones
- IAS 2015: Raltegravir Prevents Mother-to-Child HIV Transmission During Late Pregnancy
- IAS 2015: Same-day Antiretroviral Treatment Leads to Faster HIV Suppression in San Francisco
- IAS 2015: Intermittent PrEP May Be Robust Strategy for Anal Sex -- Vaginal Protection Less Certain
- IAS 2015: WHO Urges More HIV Testing Outside Clinical Settings, Targeting Those Who Need It Most
- IAS 2015: Presumptive Treatment of TB in Advanced HIV No Better than ART and Isoniazid
- IAS 2015: New NNRTI Doravirine Suppresses HIV as Well as Efavirenz But with Fewer CNS Side Effects
- IAS 2015: No HIV Infections from Partners with Fully Suppressed Virus in Landmark Trial
- IAS 2015: Opioid Substitution Therapy Combined with HIV Treatment Saves More Lives
- IAS 2015: Young Woman Stays Undetectable for 12 Years Off Treatment After Early HIV Therapy
- IAS 2015: Non-Daily PrEP Provides Extra Options, But Adherence Often Better with Daily Dosing
- IAS 2015: Vancouver Consensus Calls for Early Access to HIV Treatment and PrEP Worldwide
- IAS 2015: Maturation Inhibitor BMS-955176 Shows Good Antiviral Activity with Atazanavir
- IAS 2015: START Trial Provides Definitive Evidence of Benefits of Early HIV Treatment
- IAS 2015: Access to Screening and Treatment Are Key Issues for Hepatitis B and C
- IAS 2015: A New Era of HIV Treatment and Prevention [VIDEO]
- IAS 2015: World Health Organization to Recommend HIV Treatment for All
- Coverage of the 2015 International AIDS Society Conference
Web Design and Development by